

ENDO PHARMA LLC

Form 4

November 14, 2005

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
ENDO PHARMA LLC

2. Issuer Name **and** Ticker or Trading
Symbol
ENDO PHARMACEUTICALS
HOLDINGS INC [ENDP]

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)
320 PARK AVENUE
(Street)

3. Date of Earliest Transaction
(Month/Day/Year)
11/08/2005

____ Director ____X____ 10% Owner
____ Officer (give title below) ____ Other (specify below)

NEW YORK, NY 10022

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)
X Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value \$.01 per share	11/08/2005		X		15,427	D	\$ 2.42
Common Stock, par value \$.01 per share	11/08/2005		X		6,459	D	\$ 2.42
Common Stock, par value \$.01 per share	11/08/2005		X		7,766	D	\$ 2.42

Edgar Filing: ENDO PHARMA LLC - Form 4

Common Stock, par value \$.01 per share	11/08/2005	X	5,576	D	\$ 2.42	21,333,068	D
Common Stock, par value \$.01 per share	11/08/2005	X	25,772	D	\$ 3	21,307,296	D
Common Stock, par value \$.01 per share	11/08/2005	X	1,492	D	\$ 3	21,305,804	D
Common Stock, par value \$.01 per share	11/08/2005	X	25,749	D	\$ 3	21,280,055	D
Common Stock, par value \$.01 per share	11/08/2005	X	1,581	D	\$ 3.42	21,278,474	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Call Option (obligation to sell)	\$ 2.42	11/08/2005		X	15,427	10/13/2005 08/26/2007	Common Stock 15,427
Call Option (obligation to sell)	\$ 2.42	11/08/2005		X	6,459	10/13/2005 08/26/2007	Common Stock 6,459

Edgar Filing: ENDO PHARMA LLC - Form 4

Call Option (obligation to sell)	\$ 2.42	11/08/2005	X	7,766	10/13/2005	08/26/2007	Common Stock	7,766
Call Option (obligation to sell)	\$ 2.42	11/08/2005	X	5,576	10/13/2005	08/26/2007	Common Stock	5,576
Call Option (obligation to sell)	\$ 3	11/08/2005	X	25,772	10/13/2005	08/26/2007	Common Stock	25,772
Call Option (obligation to sell)	\$ 3	11/08/2005	X	1,492	10/13/2005	08/26/2007	Common Stock	1,492
Call Option (obligation to sell)	\$ 3	11/08/2005	X	25,749	10/13/2005	08/26/2007	Common Stock	25,749
Call Option (obligation to sell)	\$ 3.42	11/08/2005	X	1,581	10/13/2005	08/26/2007	Common Stock	1,581

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ENDO PHARMA LLC 320 PARK AVENUE NEW YORK, NY 10022			X	

Signatures

/s/ Jeffrey R. Black Chief Financial
Officer 11/11/2005

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.